CORRESP 1 filename1.htm

 

Oppenheimer & Co. Inc.

85 Broad Street

New York, NY 10004

 

June 19, 2018

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

Re:                             Catabasis Pharmaceuticals, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-225410)

 

Ladies and Gentlemen:

 

In connection with the above-captioned registration statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Oppenheimer & Co. Inc., as the representative of the underwriters, hereby joins in the request of the Company that the effective date of such registration statement be accelerated to 5:00 p.m. (New York time) on June 19, 2018, or as soon thereafter as practicable.

 

In making this request the undersigned acknowledges that the underwriters are aware of their obligations under the Act as they relate to the public offering of securities pursuant to the registration statement.

 

[Signature Page Follows]

 


 

Very truly yours,

 

OPPENHEIMER & CO. INC.
As the Representative of the Underwriters

 

 

By:

/s/ Eric Helenek

 

Name:

Eric Helenek

 

Title:

Managing Director

 

 

2